Other examples are the two trials conducted by the Seoul National University Hospital and AHS Cancer Control Alberta at which the expression of hENT1 is determined in the resected tumor material in order to decide on adjuvant gemcitabine or 5-FU (Table 4). Here, SLC29A1 is linked to neoplasm.